Disease Indications Articles
A new documentary film titled “Dismissed,” which was premiered at the National Bleeding Disorders Foundation’s Bleeding Disorders Conference in Aurora, Colo., features the lived experiences of five women with hemophilia.
The U.S. Food and Drug Administration has approved Sanofi’s Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.
SetPoint System, a neuroimmune modulation device, has been approved by the U.S. Food and Drug Administration to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response, loss of response or intolerance to one or more biological or targeted synthetic disease-modifying anti-rheumatic drugs.
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat alopecia areata (AA) in adult and paediatric patients aged 12 years and older who weigh at least 40 kilograms and are living with severe-to-very severe cases of the autoimmune disease.
The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals’ EMPAVELI (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years of age and older, to reduce proteinuria.
Scientists at the University of Florida have developed an experimental mRNA vaccine that, when combined with standard immunotherapy drugs known as immune checkpoint inhibitors, produced a strong antitumor effect in mice, which could lead to a new way of treating cancer without relying solely on surgery, radiation or chemotherapy.
A recent study shows early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders.
The U.S. Food and Drug Administration has granted accelerated approval for Novartis’ Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Autism prevalence in the U.S. has increased from one in 36 children to one in 31, according to the Centers for Disease Control and Prevention’s (CDC) latest Autism and Developmental Disabilities Monitoring (ADDM) Network survey.
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
Researchers at Moffitt Cancer Center have found that tapping into the body’s own immune system and activating a type of immune cell known as B cells could be the key to boosting the effectiveness of tumor-infiltrating lymphocyte, or TIL therapy.
The U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin (IG) therapy with low immunoglobulin A (IgA) content, as replacement therapy for individuals 2 years of age and older with primary immunodeficiency (PI).